Inflammatory bowel disease (IBD) impairs health-related quality of life.
Dr Alexandra Zahn and colleagues investigated whether the improvement in the Clinical Activity Index and Endoscopic Activity Index is correlated with health related quality of life in ulcerative colitis.
The researchers assessed whether demographic and disease-related factors influence patients' experience of health-related quality of life.
The team performed their examination in the context of their recently published study of the anti-inflammatory effect of phosphatidylcholine in ulcerative colitis.
The research team treated 60 patients with chronic active ulcerative colitis with phosphatidylcholine or placebo over 3 months.
|Demographic parameters did not influence the quality of life scores|
|Inflammatory Bowel Diseases|
Patients were asked to complete the Inflammatory Bowel Disease (IBD) Questionnaire-Deutschland before and after the study.
The correlations between Clinical Activity Index and Endoscopic Activity Index and IBD Questionnaire-Deutschland scores were calculated.
The researchers obtained demographic and disease-related factors.
A lowering of Clinical Activity Index and Endoscopic Activity Index after treatment with phosphatidylcholine improved health related quality of life.
The researchers observed that constant disease activity indexes in the placebo group accompanied constant health related quality of life.
The team also showed a correlation between Clinical Activity Index and Endoscopic Activity Index and dimensions of the IBD Questionnaire-Deutschland.
Demographic parameters did not significantly influence the IBD Questionnaire-Deutschland scores.
Dr Zahn's concludes, “This study points out the strong relationship between Clinical Activity Index and Endoscopic Activity Index and all domains of health related quality of life in patients with ulcerative colitis.”
“Therefore, the IBD Questionnaire-Deutschland is a valid and reliable assessment tool that reflects changes in the health status of ulcerative colitis patients.”
“It is a useful measure of therapeutic efficacy and should be used in clinical trials in IBD.”